This clinical study was based on experimental results obtained in nude mice grafted with human colon carcinoma, showing that injected 131I-labeled F(ab)2 and Fab fragments from high affinity anti-carcinoembryonic antigen (CEA) monoclonal antibodies (MAb) gave markedly higher ratios of tumor to normal tissue localization than intact MAb. 31 patients with known colorectal carcinoma, including 10 primary tumors, 13 local tumor recurrences, and 21 metastatic involvements, were injected with '13I-labeled F(ab')2 (a = 14) or Fab (a = 17) fragments from MAb anti-CEA. The patients were examined by emission-computerized tomography (ECT) at 6, 24, and sometimes 48 h after injection using a rotating dual head scintillation camera. All 23 primary tumors and local recurrences except one were clearly visualized on at least two sections of different tomographic planes. Interestingly, nine of these patients had almost normal circulating CEA levels, and three of the visualized tumors weighed only 3-5 g. Among 19 known metastatic tumor involvements, 14 were correctly localized by ECT. Two additional liver and several bone metastases were discovered by immunoscintiraphy. Altogether, 86% of the tumor sites were detected, 82% with F(ab')2 and 89% with Fab fragments. The contrast of the tumor images obtained with Fab fragments suggests that this improved method of immunoscintigraphy has the potential to detect early tumor recurrences and thus to increase the survival of patients. The results of this retrospective study, however, should be confirmed in a prospective study before this method can be recommended for the routine diagnosis of cancer.
Introduction
After experimental work in nude mice and in hamsters heterografted with human colon carcinoma (1, 2) , large series ofpatients have been injected with '31I-labeled, purified polyclonal antiThis work was presented in part at the 31st Annual Meeting ofthe Society ofNuclear Medicine in Los Angeles, CA, and has also appeared in abstract form (1984, J. Nucl. Med. 25:17) .
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Receivedfor publication 9 July 1985. bodies against carcinoembryonic antigen (CEA)' (3) in order to detect tumors by planar scintigraphy (4-10) (Delaloye et al., unpublished results) . In these studies some striking cases oftumor detection were obtained with what should be called the first generation ofimmunoscintigraphy (polyclonal antibodies and planar scintigraphy). Major differences emerged, however, in the interpretation of the clinical results obtained. Goldenberg's group claimed that the results obtained with the first generation of immunoscintigraphy were already clinically useful (4, 9, 10), whereas our group, despite the use of goat anti-CEA antibodies giving specific tumor to normal tissue ratios in 58 colorectal carcinoma patients, concluded that the technology of immunoscintigraphy should be improved before it could be usefully applied in the diagnosis of carcinoma (5, 6) .
In 1981, the first monoclonal anti-CEA antibody (MAb) 23, which had an affinity of 5.7 X 108 M' (11) , was studied in a series of 31 colorectal carcinoma patients tested by planar scintigraphy (12) . The results were slightly improved as compared with polyclonal antibodies, in the sense of less nonspecific accumulation of the tracer in the reticuloendothelial system, but they were not yet considered satisfactory for clinical application.
The same MAb 23 was tested in an additional series of 16 patients with colorectal carcinoma and medullary thyroid carcinomas, using for the first time emission-computerized tomography (ECT) for detection of labeled antibodies (12, 13) . With this second generation of immunoscintigraphy, the results were encouraging in terms of sensitivity (16-17 tumors detected) but the signal-to-noise ratio was not very high, in part due to the poor detection efficiency of '" I by the camera and in part to the relatively low affinity of MAb 23.
As a further way of improving this technique we produced an additional series of 26 new anti-CEA MAb, which were selected first in vitro on the basis of high affinity for CEA and absence of crossreactivity with granulocyte glycoproteins (14, 15) , and second, in vivo in the nude mouse model for good localization in human colon carcinoma heterograft (14) . The MAb with the highest affinity for CEA (5.8 X 109 M-') and no crossreactivity with granulocytes was MAb 35. In addition, F(ab')2 and Fab fragments from MAb 35 were shown to give 3 and 12 times, respectively, higher tumor to normal tissue ratios as compared with intact MAb 35, in the nude mouse model (16 Tables I-III show the clinical features for 10 patients with primary tumors (all of them were operated within 20 d after the present study), 13 patients having local recurrences with or without metastases (time between first operation and present study ranged from 1 to 28 mo; mean, 13 mo) and 8 with only distant metastases (time between first operation and study ranged from 5 to 50 mo; mean, 28 mo). The metastases were localized in the liver (n = 14), in the bone (n = 3), in the lung (n = 2), or in the peritoneum (n= 2). In four of these patients, metastatic involvement of the liver (n = 2), or bone (n = 2) was first detected by immunoscintigraphy and confirmed thereafter. Dukes The serum CEA levels were measured by a solid-phase enzyme immunoassay using three different monoclonal anti-CEA antibodies (22) .
The normal level of serum CEA using this assay ranged from 0 to 5 Asg/ liter.
Results
Tumor status and immunoscintigraphy data for all patients are summarized in Tables I-III. Table I shows that all primary tumors have been visualized by this technique with both types of fragments and regardless of the level of circulating CEA. Fig. 1 illustrates the detection of a carcinoma of the caecum on a coronal (i.e., frontal) ECT section of the lower abdomen and pelvis from patient 1. The F(ab')2 fragments from MAb anti-CEA 202 injected in this patient were avidly taken up by the tumor, as confirmed by direct measurement of the radioactivity in resected tumor and adjacent tissues (Fig. 2 A) Figure 1 . Uptake of MAb 202 F(ab'`) fragments in tumor but also in bone marrow. The coronal section (C) of patient I with a carcinoma of the caecum obtained 24 h after injection shows avid uptake of the antibody by the tumor (T) as confirmed by in vitro counting of the surgical specimen (Fig. 2 A) , but also visualization of bone marrow (BM) which seems to be related to the crossreaction of MAb 202 with granulocyte glycoproteins (15) . The colors red, yellow, green, and blue correspond to the degree of concentration of radioactivity: red is high and blue is low.
202, however, was injected in only one patient because it was found to bind to granulocytes (15) and to be taken up by the normal bone marrow, as demonstrated in patient 1 (Fig. 1) . Fragments of MAb 35 did not bind to granulocytes (15) . They were injected in the next 30 patients and did not show uptake of radioactivity in the normal bone marrow. Fig. 3 shows transverse sections taken at the same level of the middle abdomen at different times after injection of Fab fragments from MAb 35 in patient 15. The sections cut across a right colon tumor and the large abdominal vessels (aorta and inferior vena cava). At 6 h after injection vascular activity exceeded tumor activity, which was, however, already detectable. The tumor to blood circulation activity ratio increased with time, being near one at 24 h and definitely higher at 48 h. In our experience all but one primary tumor has been clearly distinguished on the 6-h scans, but the most reliable images have been obtained after 24 h. Images obtained more than 24 h after injection often had artifacts created by patient movement in the case of long data collection times or by statistical uncertainty in the case of shorter ones. The tumor of the patient presented in Fig. 3 was rather large, weighing 33 g and having a maximum diameter of 6 cm. Detectability of primary tumors by ECT, however, does not appear to be related to tumor size.
The smallest tumor in this series was detected in patient 17 after injection of Fab fiagments from MAb 35. It weighed 3 g and was a primary tumor of the descending colon situated just distal to the splenic angle. In spite of its small size, it was easily distinguished on the 6-h transverse section as a unique hot spot anterior to the left kidney (Fig. 4) . Kidneys take up radioactivity during 24 h after injection and can be used as landmarks.
It is sometimes difficult to distinguish tumor from bladder activity when the tumors are located in the lower pelvis, as in patient 18 who had a carcinomatous polyp ofthe recto-sigmoid weighing only 4.5 g, which was detected with Fab fragments of MAb 35. On the transverse section, tumor activity could not be separated from bladder activity, whereas on the 24-h sagittal section (Fig. 5 ) the tumor appeared as a well-delineated area of ectopic activity behind the bladder. The uptake of radioactivity by this tumor was confirmed by direct counting of the tissues after surgical resection (Fig. 2 C) .
The detection of a 5-g sigmoid tumor in patient 20 is demonstrated in Fig. 6 . In a coronal section of the lower abdomen obtained 24 distinct from the radioactivity in the urinary bladder. This tumor was resected 5 d after injection and the radioactivity in tumor and adjacent normal tissues was compared (Fig. 2 D) . (Tc-99m dicarboxy-propane-diphosphonate). Fig. 7 shows on the left panel a sagittal section through the thorax and upper lumbar spine and on the right panel a coronal section of the pelvis. Both sections showed multiple hot spots corresponding to uptake of the labeled antibody.
Altogether, 21 distant tumor involvements (several tumor sites in one organ or tissue were counted as one) were present and 16 were correctly localized by ECT (Tables I-IV) The sagittal section is often the most useful one, as shown here for patient 18, who presented a 4.5-g carcinomatous polyp of the rectum. 6 h after injection, tumor activity (arrow) is clearly distinct from urinary activity in the bladder (b), which is located anteriorly. 2 d after injection, the patient was operated on and specific tumor-to-normal tissues ratios were observed by direct counting of the radioactivity in tissues (Fig. 2 C) .
sponding exactly with the radiological findings. No uptake of radioactivity could be demonstrated in two small lung lesions of the other patient (patient 9), who had in addition a large liver metastasis which also undetected by ECT and a very high serum CEA level (2,500 ag/liter).
Two regional tumor metastases in the peritoneum were not detected. One was situated in the lower abdomen of patient 25, who had in addition multiple bone metastases which took up Fab fragments and the already mentioned single undetected local recurrence from this series. One may assume that the accumulation of labeled fragments in the bone metastases prevented their localization in the local and regional tumor recurrence. In the other patient with peritoneal involvement (patient 24), the sigmoid local recurrence was correctly identified, whereas the peritoneal carcinomatosis remained undetected by immunoscintigraphy. (Fig. 2 D) . L, left.
Two patients (patients 15 and 20) with primary tumors had normal liver CT scan or ultrasound examinations, whereas immunoscintigraphy showed antibody uptake in an area of the liver which proved to be photon deficient on the Tc-99m sulfur colloid ECT. In both cases, the liver metastases were confirmed at surgery. Among 12 patients with known liver metastases (as detected by ultrasound and/or CT scan), 10 had lesions that took up antibody fragments. Liver involvement was undetected in two patients, one with liver cirrhosis (patient 9) and the other with a metastasis located at the site of resection after repeated partial hepatectomy (patient 14).
ECT studies from two patients with liver metastases will be presented in further detail. The first patient (patient 12) had a large metastasis in the posterior part ofthe right lobe of the liver easily detected by ultrasound. This case is presented (Fig. 8) because it demonstrates the slow and progressive penetration of the F(ab')2 fragments within the tumor mass as well as the morphological accuracy of the ECT images.
Patient 15 was not known to have liver metastasis before immunoscintigraphy. Fig. 9 shows the corresponding transverse Our overall results are summarized in Table IV . 38 of 44 organs with tumor involvement were correctly identified. The detection rate proved to be somewhat higher with Fab (89%) than with F(ab')2 fragments (82%).
Discussion
The concept of using radiolabeled antibodies to detect hidden tumor cells (23) has been revitalized by the development of the MAb technology. For the last 7 yr, however, several thousands of patients have received injections of radiolabeled polyclonal or monoclonal antibodies directed against various tumor markers, with relatively modest clinical results in terms of precision of tumor imaging (4-10, 24-26). We were among the first to make a critical evaluation of the results obtained with polyclonal and monoclonal anti-CEA antibodies labeled with '"'I (5, 12) .
We considered that the tumor detection obtained by this method, particularly after computerized subtraction of blood pool radioactivity, was not precise and reliable enough to influence clinical decisions.
In contrast, the tumor images reported here, obtained by using ECT and the smallest fragment (Fab) of highly selected anti-CEA MAb, labeled with 123I represent a marked improvement over previously published results. The high resolution of the tomographic tumor images strongly suggests that this improved method of immunoscintigraphy has the potential to In order to obtain the necessary improvement of colon carcinoma detection by immunoscintigraphy, three factors appeared to be of particular importance: (a) the selection of the most favorable target tumor marker and the best MAb directed against this antigen, (b) the choice between intact antibodies and their F(ab')2 or Fab fragments, and (c) selection ofthe most convenient isotope. These three factors will be discussed in sequence.
Despite the theoretical disadvantage of CEA, as an antigen released into the circulation, we chose this marker because our previous clinical experience showed that we could obtain relatively good ratios of tumor to normal tissue localization despite the presence of elevated circulating CEA levels (5, 6, 12, 13) .
Two other markers associated with colon carcinoma have been identified by (33) .
The anti-CEA MAb 35 used in this study was selected out of more than 30 anti-CEA MAb by the criteria of high affinity (5.8 X 109 M-') for CEA and absence of crossreactivity with granulocyte glycoproteins (14) (15) (16) .
The selection of the antibody fragments was based on our experimental results obtained in nude mice grafted with human colon carcinoma. '3'I-labeled F(ab')2 or Fab from MAb 35 gave 3.5 and 11.7 times higher tumor to normal tissue ratios, respectively, than intact MAb 35 (16) . Furthermore, when we started to inject the Fab fragments into patients [after having used F(ab')2 in the first 13 patients of this study], we noticed an improvement in the quality of the tumor images (earlier tumor uptake, less background radioactivity in spleen and liver); thus we injected all the following patients with Fab from MAb 35. 308 In fact, 6 out of 8 of the figures of ECT studies presented here were obtained after injection of Fab from MAb 35. Our selection of the Fab fragments is in agreement with Larson et al. (34) , who also used Fab of high affinity MAb for imaging of melanomas. It should be noted, however, that in some experimental models, F(ab')2 fragments and even intact antibodies have been reported to give better tumor localization than Fab (35, 36) . The poor results with these Fab fragments may be explained by a too low affinity of the antibody. A relatively low affinity becomes a limiting factor when a fragment with a single binding site is used. In our experience, the Fab fragments from MAb with an affinity lower than 5 X 108 M-' perform less well than F(ab')2 (Buchegger et al., manuscript in preparation). In addition, large amounts of antibody fragments labeled with "'In through the bifunctional chelating agent diethylenetriamine-pentaacetic acid may accumulate in the kidney (36) , whereas kidney accumulation of '3'1-labeled MAb fragments was much less important in our experimental studies (16).
The choice ofthe isotope is controversial. Tc-99m, the most convenient and widely used isotope in nuclear medicine, would be ideal ifit had a physical half-life slightly longer than 6 h. The methodology to label antibodies with a sufficiently high specific activity of this isotope has been developed and the in vivo localization ofTc-99m-labeled MAb anti-cardiac myosin in myocardial infarction has been reported (37) . According to most experimental results, however, it takes at least 24 h to obtain a good localization in solid tumors; thus, the 6-h half-life of Tc-99m appears to be too short.
"'In has a favorable half-life of 2.7 d, and excellent experimental results have been obtained with "'In-labeled intact antitumor antibodies (36) . When "'In-labeled antibodies have been injected into patients, however, a very high nonspecific uptake has always been observed in the reticuloendothelium, especially in the liver (26, 38) , even when the DTPA coupling was performed under mild conditions (25, 39) . Since high nonspecific liver uptake may interfere with the detection of liver metastases, we considered this label not to be optimal for the evaluation of colon carcinoma patients by immunoscintigraphy.
'l'I has the advantage of a long half-life (8 d) and has been used by Chatal et al. (31) One of the limitations of the '231-labeled MAb fragment method is the uptake of iodine by the stomach and its rapid elimination by the urinary tract. These regular nonspecific accumulations, however, may also be used as anatomical landmarks, as previously suggested by Berche et al. (13) , and thus be helpful for the topographic characterization of hot spots. Interestingly, two of the small tumors reported here, weighing 3 and 4.5 g, were detected near a very radioactive organ, the first one near the left kidney (Fig. 4 ) and the second one behind the urinary bladder (Fig. 5) . One of the greatest advantages of ECT is that it allows a distinction between tumor uptake of radiolabeled antibodies from physiological organ concentration and circulating radioactivity, without the need to use computerized subtraction techniques which are prone to artifacts (19) . Another, more important, limitation of antibody fragments which has to be mentioned is that the percentage of the injected dose which localizes in tumor remains relatively low (<1%). Even in the experimental animal, where we reached tumor to normal tissue ratios of 82 with Fab fragments from MAb 35, the percentage of injected dose was four times lower than for intact MAb 35 (16). Therefore, if one considers the injection of radioactive antibodies for therapeutic purposes, we are not certain that Fab fragments are the best carrier, as proposed by Larson et al. (33, 34) . Intact antibodies with their longer biological halflife may have a better chance to deliver the necessary dose of radioactivity into the tumor, as suggested by Order et al. (40) . Intact antibodies, however, will give higher background radioactivity in the reticuloendothelial system. Since the therapeutic index is determined by the ratio of radiation delivered to the tumor to that delivered to the sensitive normal organs (33) , it is possible that a fragment of intermediary size such as F(ab')2 will be the most appropriate carrier for antibody-guided radiotherapy. We have recently injected 100 mCi of '"'I coupled to 10 mg of F(ab')2 from MAb 35 into the hepatic artery of four patients with advanced liver metastases of colon carcinoma. The treatment was well tolerated, that is, no bone marrow toxicity was observed, but no evidence of significant regression of the large hepatic metastases was obtained (41) .
For diagnostic purposes, however, the use of Fab fragments labeled with 123I and detected by ECT, as described here, appears to offer the best potential for the detection of early tumor recurrences, a necessary condition to improve curability and survival in patients with colon carcinoma.
